IL108844A - Drugs containing rilosol for the treatment of neuro-AIDS - Google Patents

Drugs containing rilosol for the treatment of neuro-AIDS

Info

Publication number: IL108844A
Authority: IL; Israel
Prior art keywords: riluzole; treatment; neuro; aids; medicament
Prior art date: 1993-03-05

Application number

IL108844A

Other languages

English (en)

Hebrew (he)

Other versions

IL108844A0 (en

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-05

Filing date

1994-03-03

Publication date

1998-01-04

1994-03-03 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1994-06-24 Publication of IL108844A0 publication Critical patent/IL108844A0/xx

1998-01-04 Publication of IL108844A publication Critical patent/IL108844A/en

Links

229960004181 riluzole Drugs 0.000 title claims abstract description 14
FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title claims abstract description 13
239000003814 drug Substances 0.000 title claims description 12
150000003839 salts Chemical class 0.000 claims abstract description 11
208000030507 AIDS Diseases 0.000 claims abstract description 9
239000003085 diluting agent Substances 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
208000021642 Muscular disease Diseases 0.000 claims description 3
201000009623 Myopathy Diseases 0.000 claims description 3
206010060860 Neurological symptom Diseases 0.000 claims description 3
208000022873 Ocular disease Diseases 0.000 claims description 3
239000002671 adjuvant Substances 0.000 claims description 3
208000010877 cognitive disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
201000001119 neuropathy Diseases 0.000 claims description 3
230000007823 neuropathy Effects 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
208000033808 peripheral neuropathy Diseases 0.000 claims 2
150000001875 compounds Chemical class 0.000 abstract description 2
239000000203 mixture Substances 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
238000000034 method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
230000006576 neuronal survival Effects 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000008119 colloidal silica Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000016273 neuron death Effects 0.000 description 2
229940096364 riluzole 50 mg Drugs 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102100021696 Syncytin-1 Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
VYEYJCBEXFTGBN-UHFFFAOYSA-N acetic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 VYEYJCBEXFTGBN-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000002609 medium Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
-1 phenolphthalinate Chemical compound 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000002966 varnish Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Virology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

IL108844A 1993-03-05 1994-03-03 Drugs containing rilosol for the treatment of neuro-AIDS IL108844A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9302568A FR2702148B1 (fr)	1993-03-05	1993-03-05	Application d'anticonvulsivants dans le traitement du neuro-sida.

Publications (2)

Publication Number	Publication Date
IL108844A0 IL108844A0 (en)	1994-06-24
IL108844A true IL108844A (en)	1998-01-04

Family

ID=9444690

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL108844A IL108844A (en)	1993-03-05	1994-03-03	Drugs containing rilosol for the treatment of neuro-AIDS
IL10884594A IL108845A0 (en)	1993-03-05	1994-03-03	Use of anticonvulsants in the treatment of neuro-aids
IL10884694A IL108846A0 (en)	1993-03-05	1994-03-03	Use of lamortrigine in the treatment of neuro aids

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL10884594A IL108845A0 (en)	1993-03-05	1994-03-03	Use of anticonvulsants in the treatment of neuro-aids
IL10884694A IL108846A0 (en)	1993-03-05	1994-03-03	Use of lamortrigine in the treatment of neuro aids

Country Status (23)

Country	Link
US (2)	US5629312A (cs)
EP (3)	EP0687177B1 (cs)
JP (3)	JPH08507509A (cs)
KR (3)	KR960700721A (cs)
AT (2)	ATE147981T1 (cs)
AU (3)	AU6143894A (cs)
CA (3)	CA2154571A1 (cs)
CZ (3)	CZ285339B6 (cs)
DE (2)	DE69401577T2 (cs)
DK (2)	DK0687177T3 (cs)
ES (2)	ES2096455T3 (cs)
FR (1)	FR2702148B1 (cs)
GR (2)	GR3022356T3 (cs)
HU (3)	HU9502584D0 (cs)
IL (3)	IL108844A (cs)
NO (3)	NO307687B1 (cs)
PL (3)	PL310474A1 (cs)
PT (1)	PT687176E (cs)
RU (1)	RU2157205C2 (cs)
SK (3)	SK107595A3 (cs)
UA (1)	UA41355C2 (cs)
WO (3)	WO1994020110A1 (cs)
ZA (2)	ZA941530B (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5866597A (en) *	1993-03-19	1999-02-02	Glaxo Wellcome Inc.	Use of triazine compounds for the treatment of memory and learning disorders
GB9424766D0 (en) *	1994-12-07	1995-02-08	Wellcome Found	Pharmaceutical composition
GB9512854D0 (en) *	1995-06-23	1995-08-23	Wellcome Found	Novel formulation
DE19603984A1 (de) *	1996-02-05	1997-08-07	Bayer Ag	Granulate von Triazinen
US20020022056A1 (en)	1997-02-14	2002-02-21	Burkhard Schlutermann	Oxacarbazepine film-coated tablets
CO4920215A1 (es) *	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5922746A (en) *	1997-03-27	1999-07-13	Allergan	Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
GB9721497D0 (en) *	1997-10-09	1997-12-10	Ciba Geigy Ag	Organic compounds
FR2774592B1 (fr) *	1998-02-06	2000-03-17	Rhone Poulenc Rorer Sa	Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2774908B1 (fr) *	1998-02-17	2000-06-23	Centre Nat Rech Scient	Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
FR2787028B1 (fr) *	1998-12-15	2002-10-18	Aventis Pharma Sa	Utilisation du riluzole dans le traitement des traumatismes acoustiques
EP1173175A1 (en) *	1999-04-29	2002-01-23	Centre National De La Recherche Scientifique (Cnrs)	A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
US7479498B2 (en) *	1999-08-23	2009-01-20	Phoenix Biosciences, Inc.	Treatments for viral infections
GB9925962D0 (en) *	1999-11-02	1999-12-29	Novartis Ag	Organic compounds
FR2801217B1 (fr) *	1999-11-24	2002-12-06	Aventis Pharma Sa	Association de riluzole et de gabapentine et son utilisation comme medicament
GB9930058D0 (en)	1999-12-20	2000-02-09	Novartis Ag	Organic compounds
US6207179B1 (en) *	2000-05-18	2001-03-27	Phoenix Scientific, Inc.	Parasiticidal formulation for animals and a method of making this formulation
CA2471666C (en)	2004-06-18	2009-10-13	Apotex Pharmachem Inc.	An improved process for the preparation of oxcarbazepine and related intermediates
EP2201963B1 (en) *	2005-04-05	2016-01-27	Yale University	Glutamate modulating agents in the treatment of mental disorders
US20060252745A1 (en)	2005-05-06	2006-11-09	Almeida Jose L D	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2910811B1 (fr) *	2007-01-03	2009-07-10	Ass Pour Le Dev De La Biothera	Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
GB0700773D0 (en)	2007-01-15	2007-02-21	Portela & Ca Sa	Drug therapies
FR2957077B1 (fr) *	2010-03-02	2012-04-13	Univ Dauvergne Clermont I	Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
HUE046869T2 (hu) *	2014-11-21	2020-04-28	Biohaven Therapeutics Ltd	Riluzol szublingvális formulációja
KR102729925B1 (ko) *	2021-02-24	2024-11-14	브이지피 아이피씨오 엘엘씨	증발기 코일용 발포 세정제
US12605388B2 (en)	2024-09-25	2026-04-21	Azurity Pharmaceuticals Ireland Limited	Lamotrigine salts, co-crystals, and compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2492258A1 (fr) *	1980-10-17	1982-04-23	Pharmindustrie	Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) *	1980-10-17	1984-02-14	Ciba-Geigy Corporation	Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) *	1986-05-30	1986-07-02	Wellcome Found	Triazine salt
US4826860A (en) *	1987-03-16	1989-05-02	Warner-Lambert Company	Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
FR2619712B1 (fr) *	1987-08-25	1990-08-31	Rhone Poulenc Sante	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
FR2619713B1 (fr) *	1987-08-25	1990-08-31	Rhone Poulenc Sante	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
US4918090A (en) *	1988-01-25	1990-04-17	Warner-Lambert Company	Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
EP0435826A1 (de) *	1989-12-27	1991-07-03	Ciba-Geigy Ag	Intravenöse Lösungen für Status Epilepticus
US5326570A (en) *	1991-07-23	1994-07-05	Pharmavene, Inc.	Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
FR2688138B1 (fr) *	1992-03-06	1995-05-05	Rhone Poulenc Rorer Sa	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
JPH07308499A (ja) *	1994-05-20	1995-11-28	Brother Ind Ltd	衣類乾燥機

1993
- 1993-03-05 FR FR9302568A patent/FR2702148B1/fr not_active Expired - Lifetime
1994
- 1994-02-25 US US08/530,253 patent/US5629312A/en not_active Expired - Fee Related
- 1994-02-25 ES ES94908376T patent/ES2096455T3/es not_active Expired - Lifetime
- 1994-02-25 UA UA95083996A patent/UA41355C2/uk unknown
- 1994-02-25 CZ CZ952259A patent/CZ285339B6/cs not_active IP Right Cessation
- 1994-02-25 DE DE69401577T patent/DE69401577T2/de not_active Expired - Fee Related
- 1994-02-25 PT PT94908374T patent/PT687176E/pt unknown
- 1994-02-25 EP EP94908376A patent/EP0687177B1/fr not_active Expired - Lifetime
- 1994-02-25 SK SK1075-95A patent/SK107595A3/sk unknown
- 1994-02-25 WO PCT/FR1994/000209 patent/WO1994020110A1/fr not_active Ceased
- 1994-02-25 ES ES94908374T patent/ES2157252T3/es not_active Expired - Lifetime
- 1994-02-25 CA CA002154571A patent/CA2154571A1/fr not_active Abandoned
- 1994-02-25 AT AT94908376T patent/ATE147981T1/de active
- 1994-02-25 SK SK1074-95A patent/SK107495A3/sk unknown
- 1994-02-25 DE DE69427344T patent/DE69427344T2/de not_active Expired - Lifetime
- 1994-02-25 HU HU9502584A patent/HU9502584D0/hu unknown
- 1994-02-25 PL PL94310474A patent/PL310474A1/xx unknown
- 1994-02-25 CZ CZ952260A patent/CZ226095A3/cs unknown
- 1994-02-25 SK SK1076-95A patent/SK279659B6/sk not_active IP Right Cessation
- 1994-02-25 AU AU61438/94A patent/AU6143894A/en not_active Abandoned
- 1994-02-25 RU RU95121731/14A patent/RU2157205C2/ru not_active IP Right Cessation
- 1994-02-25 CA CA002154572A patent/CA2154572C/fr not_active Expired - Fee Related
- 1994-02-25 WO PCT/FR1994/000210 patent/WO1994020108A1/fr not_active Ceased
- 1994-02-25 AT AT94908374T patent/ATE201597T1/de active
- 1994-02-25 AU AU61437/94A patent/AU675118B2/en not_active Ceased
- 1994-02-25 AU AU61439/94A patent/AU675119B2/en not_active Ceased
- 1994-02-25 JP JP6519649A patent/JPH08507509A/ja active Pending
- 1994-02-25 KR KR1019950703734A patent/KR960700721A/ko not_active Withdrawn
- 1994-02-25 HU HU9502585A patent/HU217132B/hu not_active IP Right Cessation
- 1994-02-25 JP JP6519648A patent/JPH08507508A/ja active Pending
- 1994-02-25 DK DK94908376.0T patent/DK0687177T3/da active
- 1994-02-25 CZ CZ952261A patent/CZ284423B6/cs unknown
- 1994-02-25 DK DK94908374T patent/DK0687176T3/da active
- 1994-02-25 EP EP94908374A patent/EP0687176B1/fr not_active Expired - Lifetime
- 1994-02-25 HU HU9502583A patent/HUT73434A/hu unknown
- 1994-02-25 CA CA002154573A patent/CA2154573A1/fr not_active Abandoned
- 1994-02-25 JP JP51964794A patent/JP3578174B2/ja not_active Expired - Fee Related
- 1994-02-25 PL PL94310476A patent/PL310476A1/xx unknown
- 1994-02-25 PL PL94310475A patent/PL310475A1/xx unknown
- 1994-02-25 KR KR1019950703733A patent/KR960700723A/ko not_active Withdrawn
- 1994-02-25 EP EP94908375A patent/EP0687179A1/fr not_active Withdrawn
- 1994-02-25 KR KR1019950703732A patent/KR100318168B1/ko not_active Expired - Fee Related
- 1994-02-25 WO PCT/FR1994/000208 patent/WO1994020103A1/fr not_active Ceased
- 1994-03-03 IL IL108844A patent/IL108844A/en not_active IP Right Cessation
- 1994-03-03 IL IL10884594A patent/IL108845A0/xx unknown
- 1994-03-03 IL IL10884694A patent/IL108846A0/xx not_active IP Right Cessation
- 1994-03-04 ZA ZA941530A patent/ZA941530B/xx unknown
- 1994-03-04 ZA ZA941525A patent/ZA941525B/xx unknown
1995
- 1995-02-28 US US08/396,106 patent/US5624945A/en not_active Expired - Lifetime
- 1995-08-28 NO NO953370A patent/NO307687B1/no not_active IP Right Cessation
- 1995-08-28 NO NO953371A patent/NO953371L/no unknown
- 1995-08-28 NO NO953372A patent/NO953372D0/no unknown
1997
- 1997-01-23 GR GR960402768T patent/GR3022356T3/el unknown
2001
- 2001-05-31 GR GR20010400060T patent/GR3035957T3/el unknown

Also Published As

Publication number	Publication date
ATE147981T1 (de)	1997-02-15
EP0687176A1 (fr)	1995-12-20
KR960700721A (ko)	1996-02-24
SK279659B6 (sk)	1999-02-11
ES2157252T3 (es)	2001-08-16
JP3578174B2 (ja)	2004-10-20
PL310475A1 (en)	1995-12-11
FR2702148B1 (fr)	1995-04-07
PT687176E (pt)	2001-09-28
RU2157205C2 (ru)	2000-10-10
GR3022356T3 (en)	1997-04-30
HUT73433A (en)	1996-07-29
CZ285339B6 (cs)	1999-07-14
NO953370D0 (no)	1995-08-28
NO953372L (no)	1995-08-28
SK107695A3 (en)	1996-06-05
EP0687177B1 (fr)	1997-01-22
CA2154572A1 (fr)	1994-09-15
HU9502584D0 (en)	1995-11-28
PL310476A1 (en)	1995-12-11
SK107495A3 (en)	1996-06-05
DE69401577D1 (de)	1997-03-06
US5629312A (en)	1997-05-13
EP0687176B1 (fr)	2001-05-30
NO953370L (no)	1995-08-28
US5624945A (en)	1997-04-29
DE69427344D1 (de)	2001-07-05
DE69427344T2 (de)	2002-04-25
JPH08507509A (ja)	1996-08-13
IL108844A0 (en)	1994-06-24
NO953371D0 (no)	1995-08-28
SK107595A3 (en)	1996-06-05
CA2154572C (fr)	2006-06-06
HUT73434A (en)	1996-07-29
CZ226095A3 (en)	1995-12-13
WO1994020103A1 (fr)	1994-09-15
KR100318168B1 (ko)	2002-06-20
AU675119B2 (en)	1997-01-23
UA41355C2 (uk)	2001-09-17
HU9502583D0 (en)	1995-11-28
CA2154571A1 (fr)	1994-09-15
WO1994020110A1 (fr)	1994-09-15
AU675118B2 (en)	1997-01-23
EP0687179A1 (fr)	1995-12-20
DK0687176T3 (da)	2001-07-30
JPH08507508A (ja)	1996-08-13
HU9502585D0 (en)	1995-11-28
CZ225995A3 (en)	1995-12-13
AU6143994A (en)	1994-09-26
IL108845A0 (en)	1994-06-24
HU217132B (hu)	1999-11-29
CA2154573A1 (fr)	1994-09-15
PL310474A1 (en)	1995-12-11
KR960700723A (ko)	1996-02-24
KR960700716A (ko)	1996-02-24
DK0687177T3 (da)	1997-02-10
NO307687B1 (no)	2000-05-15
ATE201597T1 (de)	2001-06-15
EP0687177A1 (fr)	1995-12-20
GR3035957T3 (en)	2001-08-31
ZA941530B (en)	1994-10-06
AU6143894A (en)	1994-09-26
IL108846A0 (en)	1994-06-24
DE69401577T2 (de)	1997-05-15
CZ284423B6 (cs)	1998-11-11
ZA941525B (en)	1994-11-09
FR2702148A1 (fr)	1994-09-09
NO953371L (no)	1995-08-28
AU6143794A (en)	1994-09-26
WO1994020108A1 (fr)	1994-09-15
JPH08507507A (ja)	1996-08-13
CZ226195A3 (en)	1995-12-13
NO953372D0 (no)	1995-08-28
ES2096455T3 (es)	1997-03-01

Legal Events

Date	Code	Title
1998-06-15	FF	Patent granted
1998-12-27	KB	Patent renewed
2000-08-13	KB	Patent renewed
2004-05-12	KB	Patent renewed
2012-03-29	KB	Patent renewed
2014-09-30	EXP	Patent expired

Publication	Publication Date	Title
US5624945A (en)	1997-04-29	Use of riluzole for the treatment of neuro-aids
RU2221563C2 (ru)	2004-01-20	Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
US5527814A (en)	1996-06-18	Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis
US5656647A (en)	1997-08-12	Application of riluzole for promoting restoration following radiation
FR2702149A1 (fr)	1994-09-09	Application de la lamotrigine dans le traitement du neuro-sida.
DE69630561T2 (de)	2004-06-09	Verwendung von 4-Amino-6-hydroxypyrazolo[3,4-d]pyrimidin zur Herstellung eines blutdrucksenkenden Mittels
AU2171199A (en)	1999-08-23	Use of 2-amino-6- trifluoromehthoxy- benzothiazole for preventing or treating cerebellum dysfunction
FR2702151A1 (fr)	1994-09-09	Application d'anticonvulsivants dans le traitement du neuro-sida.
DE10203103A1 (de)	2003-08-07	Pramipexol zur Behandlung von HIV Demenz